keyword
https://read.qxmd.com/read/38628332/interstitial-keratitis-presenting-as-the-ocular-manifestation-of-undiagnosed-hidradenitis-suppurativa
#21
Kendahl Lyle, Joseph L Zimmer, Wesley M Gillette, Matthew S Recko
Interstitial keratitis is defined as nonulcerative inflammation of the corneal stroma resulting from a bacterial or viral infection, parasitic antigen, or autoimmune response. Hidradenitis suppurativa is an inflammatory skin condition that presents with painful and inflamed boils in apocrine gland-bearing regions of the body, typically with onset around puberty, and ocular comorbidities exist in only a small percentage of these patients. Herein, we describe a unique ocular presentation of hidradenitis suppurativa including pronounced bilateral interstitial keratitis and association with high titer c-ANCA (antineutrophil cytoplasmic antibodies)...
2024: Proceedings of the Baylor University Medical Center
https://read.qxmd.com/read/38623950/use-of-biologics-for-psoriasis-in-solid-organ-transplant-recipients
#22
JOURNAL ARTICLE
Marta Costa Blasco, Claire Doyle, Sophie Diong, Siona Ni Raghallaigh
Biologics have significantly advanced the treatment of inflammatory disorders, including psoriasis. However, their use in immunosuppressed patients, such as those with solid-organ transplants, is less understood. These patients often face dermatological issues, but inflammatory skin diseases are rare due to their immunosuppressive treatments. Our study aims to assess biologics' effectiveness in such immunocompromised patients. We report a case from our institution of a 29-year-old man with a history of psoriasis, who underwent a kidney transplant and later developed erythroderma...
April 16, 2024: Australasian Journal of Dermatology
https://read.qxmd.com/read/38617809/real-world-maintenance-phase-persistence-on-ustekinumab-and-adalimumab-in-ulcerative-colitis
#23
JOURNAL ARTICLE
Maryia Zhdanava, Sumesh Kachroo, Aditi Shah, Zhijie Ding, Patrick Lefebvre, Ruizhi Zhao, Caroline Kerner, Dominic Pilon
PURPOSE: To describe real-world persistence in bio-naïve and bio-experienced adults with ulcerative colitis (UC) treated with ustekinumab, a recently approved anti-interleukin 12/23 antibody, or adalimumab, an anti-TNF biologic. METHODS: This is a descriptive, retrospective cohort study. Patients initiating ustekinumab or adalimumab (index date, between 10/21/2019 and 08/13/2021) were selected from the Komodo Health comprehensive dataset and stratified into bio-naïve and bio-experienced subgroups based on biologic use 12 months pre-index date...
2024: Patient Preference and Adherence
https://read.qxmd.com/read/38616534/successful-use-of-adalimumab-in-treating-granuloma-faciale-resistant-to-traditional-therapies
#24
JOURNAL ARTICLE
Martina Mussi, Corrado Zengarini, Filippo Viviani, Lidia Sacchelli, Alessandro Pileri, Federico Bardazzi
No abstract text is available yet for this article.
April 14, 2024: Australasian Journal of Dermatology
https://read.qxmd.com/read/38612528/genetic-variants-associated-with-biological-treatment-response-in-inflammatory-bowel-disease-a-systematic-review
#25
REVIEW
Javier Plaza, Alejandro Mínguez, Guillermo Bastida, Remedios Marqués, Pilar Nos, Jose Luis Poveda, Inés Moret-Tatay
Inflammatory bowel disease (IBD) is a chronic inflammatory disorder of the digestive tract usually characterized by diarrhea, rectal bleeding, and abdominal pain. IBD includes Crohn's disease and ulcerative colitis as the main entities. IBD is a debilitating condition that can lead to life-threatening complications, involving possible malignancy and surgery. The available therapies aim to achieve long-term remission and prevent disease progression. Biologics are bioengineered therapeutic drugs that mainly target proteins...
March 27, 2024: International Journal of Molecular Sciences
https://read.qxmd.com/read/38607317/activated-and-na%C3%A3-ve-allogenic-human-placental-mesenchymal-stromal-cells-exert-an-immunomodulatory-effect-on-hidradenitis-suppurativa-patient-peripheral-blood-mononuclear-cells
#26
JOURNAL ARTICLE
Vaiva Jariene, Paulius Valiukevicius, Justinas Maciulaitis, Ugne Kuzaityte, Ruta Insodaite, Ieva Ciapiene, Romaldas Maciulaitis, Skaidra Valiukeviciene
This pilot study aimed to evaluate the immunomodulatory effect of placental mesenchymal stem/stromal cells (MSCs) on peripheral blood mononuclear cells (PBMCs) from patients with hidradenitis suppurativa (HS). Blood samples were collected from 3 healthy and 3 patients with HS. Isolated PBMCs were stained with carboxyfluorescein succinimidyl ester (CFSE) and stimulated with phorbol 12-myristate 13-acetate (PMA)/Ionomycin solution. The PBMCs of patients with HS were co-cultured with naïve MSCs (n-MSCs), activated with tumor necrosis factor (TNF)-α (10 ng/mL) and interferon (IFN)-γ (10 ng/mL) MSCs (a-MSCs), or adalimumab (30 μg/mL)...
April 12, 2024: Journal of Interferon & Cytokine Research
https://read.qxmd.com/read/38602836/an-evaluation-of-secukinumab-for-the-treatment-of-moderate-to-severe-hidradenitis-suppurativa
#27
REVIEW
Dimitra Stergianou, Theodora Kanni, Christina Damoulari, Evangelos Giamarellos-Bourboulis
INTRODUCTION: Until recently, biologic therapy for hidradenitis suppurativa was limited to anti-tumor necrosis factor (TNF) blockade with adalimumab (ADA). However, not all patients respond to treatment with ADA. This highlighted the need for more therapeutic options. Interleukin (IL)-17/T-helper17 (Th17) axis may play an important role in the pathophysiology of HS. Recently, the IL-17A inhibitor secukinumab, which targets IL-17A specifically and prevents it from interacting with the IL-17 receptor, has been FDA-approved for HS...
April 11, 2024: Expert Opinion on Biological Therapy
https://read.qxmd.com/read/38599251/a-tnf-%C3%AE-inhibitor-abolishes-sepsis-induced-cognitive-impairment-in-mice-by-modulating-acetylcholine-and-nitric-oxide-homeostasis-bdnf-release-and-neuroinflammation
#28
JOURNAL ARTICLE
Mehmet Öz, Hüseyin Erdal
Neurodegenerative disorders have a pathophysiology that heavily involves neuroinflammation. In this study, we used lipopolysaccharide (LPS) to create a model of cognitive impairment by inducing systemic and neuroinflammation in experimental animals. LPS was injected intraperitoneally at a dose of 0.5mg/kg during the last seven days of the study. Adalimumab (ADA), a TNF-α inhibitor, was injected at a dose of 10mg/kg a total of 3 times throughout the study. On the last two days of the experiment, 50mg/kg of curcumin was administered orally as a positive control group...
April 8, 2024: Behavioural Brain Research
https://read.qxmd.com/read/38599062/effect-of-adalimumab-as-an-anti-inflammatory-agent-on-gene-expression-of-retinal-pigment-epithelial-cells
#29
JOURNAL ARTICLE
M Hossein Nowroozzadeh, Mojtaba Yousefi, Mostafa Abuali, Fatemeh Sanie-Jahromi
Adalimumab (ADA) is an anti-inflammatory antibody that has FDA approval as a systemic medication for treating noninfectious uveitis. It is also provisionally being investigated as an intravitreal injection for various retinal conditions. This study aimed to assess the effect of ADA on apoptotic, inflammatory, and fibrogenesis gene expression at mRNA and protein levels in retinal pigment epithelial (RPE) cells. RPEs were treated with serial concentrations of ADA (0.5x, x, 2x, and 4x; [x = 250 µg/mL]) for 24 hours...
April 9, 2024: Biomedicine & Pharmacotherapy
https://read.qxmd.com/read/38597123/switch-from-adalimumab-to-brodalumab-as-a-possible-trigger-factor-for-the-onset-of-pyoderma-gangrenosum
#30
Giorgia Salvia, Matteo Bevilacqua, Flavia Manzo Margiotta, Alessandra Michelucci, Giammarco Granieri, Cristian Fidanzi, Valentina Dini, Marco Romanelli, Carlo Mazzatenta
No abstract text is available yet for this article.
April 10, 2024: Australasian Journal of Dermatology
https://read.qxmd.com/read/38597096/brodalumab-for-moderate-severe-hidradenitis-suppurativa-an-open-label-multicentric-cohort-study-in-real-clinical-practice
#31
JOURNAL ARTICLE
Guiovana Fernanda Osorio-Gómez, Juan Ortiz-Álvarez, Delia Diaz-Ceca, Cesar Guijarro-Sánchez, Julián Conejo-Mir Sánchez, Pablo Fernández Crehuet
INTRODUCTION: The use of biological therapy is becoming increasingly common in patients with hidradenitis suppurativa (HS). Levels of serum TNF-alfa and IL17 support the role of an immune system dysregulation in the pathogenesis of HS. Brodalumab targets the receptor A of IL-17, thus having a promising role in the treatment of HS. MATERIAL AND METHODS: A multicenter retrospective observational open-label study was conducted in two tertiary hospitals. Adults with moderate to severe HS under treatment with brodalumab 210 mg at week 0, 1, 2 and then every 2 weeks were included and assessed at weeks 0 and 16 which was the median follow-up time...
April 10, 2024: Australasian Journal of Dermatology
https://read.qxmd.com/read/38596599/treatment-of-subcorneal-pustular-dermatosis-without-dapsone-a-case-report-and-review-of-the-literature
#32
Lindsey J Wanberg, Brittney Schultz, Amrita Goyal
Subcorneal pustular dermatosis (SPD) is a rare neutrophilic dermatosis characterized by pustules on the trunk and intertriginous areas. While oral dapsone is the first-line treatment for SPD, alternative options are necessary for patients with glucose-6-phosphate dehydrogenase deficiency, drug hypersensitivity reactions, or refractory disease. To date, no consensus exists regarding next-best agents for SPD. In this report, we present a patient with significant SPD who developed dapsone hypersensitivity syndrome and then was successfully treated with colchicine and adalimumab...
2024: Case Reports in Dermatological Medicine
https://read.qxmd.com/read/38596579/aesthetic-mandibular-angloplasty-to-improve-patient-quality-of-life-in-chronic-recurrent-multifocal-osteomyelitis
#33
Yun Yong Park, Bumjin Park
Chronic recurrent multifocal osteomyelitis (CRMO) is a rare autoimmune disease that typically develops during adolescence and primarily affects women. CRMO primarily targets the bone in arms and legs, with sporadic occurrences in the mandible. CRMO is typically managed with medical treatment, and the efficacy of surgery remains controversial. Complications of surgery include massive bleeding and potential flare-up of CRMO symptoms. Herein, we report a patient with CRMO who had lesions in the bilateral rami of the mandible treated with aesthetic mandibular angloplasty...
April 2024: Plastic and Reconstructive Surgery. Global Open
https://read.qxmd.com/read/38595016/comparative-efficacy-and-therapeutic-positioning-of-biologics-in-hidradenitis-suppurativa-a-systematic-review-with-network-meta-analysis-of-randomised-trials
#34
REVIEW
Husein Husein-ElAhmed, Sara Husein-ElAhmed
Background Hidradenitis suppurativa (HS) is a challenging inflammatory skin condition. Recently, many different biologics have been tested for HS, but the paucity of head-to-head comparative trials makes it difficult to determine the real value of each biological intervention. We aimed to determine the relative efficacy among biologics in treating moderate-to-severe HS throughout a network meta-analysis (NMA) and, to identify which pathogenetic pathways may be the most appropriate to target. Methods We comprehensively identified studies in 3 databases and clinicaltrials...
February 28, 2024: Indian Journal of Dermatology, Venereology and Leprology
https://read.qxmd.com/read/38594435/a-prediction-model-for-successful-increase-of-adalimumab-dose-intervals-in-patients-with-crohn-s-disease-secondary-analysis-of-the-pragmatic-open-label-randomised-controlled-non-inferiority-ladi-trial
#35
JOURNAL ARTICLE
Reinier C A van Linschoten, Fenna M Jansen, Renske W M Pauwels, Lisa J T Smits, Femke Atsma, Wietske Kievit, Dirk J de Jong, Annemarie C de Vries, Paul J Boekema, Rachel L West, Alexander G L Bodelier, Ingrid A M Gisbertz, Frank H J Wolfhagen, Tessa E H Römkens, Maurice W M D Lutgens, Adriaan A van Bodegraven, Bas Oldenburg, Marieke J Pierik, Maurice G V M Russel, Nanne K de Boer, Rosalie C Mallant-Hent, Pieter C J Ter Borg, Andrea E van der Meulen-de Jong, Jeroen M Jansen, Sita V Jansen, Adrianus C I T L Tan, C Janneke van der Woude, Frank Hoentjen
BACKGROUND: In the pragmatic open-label randomised controlled non-inferiority LADI trial we showed that increasing adalimumab (ADA) dose intervals was non-inferior to conventional dosing for persistent flares in patients with Crohn's disease (CD) in clinical and biochemical remission. AIMS: To develop a prediction model to identify patients who can successfully increase their ADA dose interval based on secondary analysis of trial data. METHODS: Patients in the intervention group of the LADI trial increased ADA intervals to 3 and then to 4 weeks...
April 9, 2024: Digestive Diseases and Sciences
https://read.qxmd.com/read/38592203/an-observational-study-in-the-real-clinical-practice-of-the-treatment-of-noninfectious-uveitis
#36
JOURNAL ARTICLE
Mar Esteban-Ortega, Martina Steiner, Cristina Andreu-Vázquez, Israel Thuissard-Vasallo, Alvaro Díaz-Rato, Santiago Muñoz-Fernández
BACKGROUND: The aim of this study was to describe the characteristics of patients with uveitis associated with an immunologic or idiopathic disease that requires immunosuppressive treatment and the response to such treatments in real clinical practice. METHODS: An observational, descriptive, longitudinal, and retrospective study of a cohort of patients diagnosed with noninfectious uveitis was performed. To assess the response to treatment, we evaluated the change in visual acuity, vitritis, and the presence of macular edema...
February 28, 2024: Journal of Clinical Medicine
https://read.qxmd.com/read/38588819/bimekizumab-safety-in-moderate-to-severe-plaque-psoriasis-rates-of-hepatic-events-and-changes-in-liver-parameters-over-2-years-in-randomized-phase-3-3b-trials
#37
JOURNAL ARTICLE
Mark Lebwohl, Joseph F Merola, Bruce Strober, April Armstrong, Ayumi Yoshizaki, Paolo Gisondi, Balint Szilagyi, Luke Peterson, Dirk de Cuyper, Nancy Cross, Owen Davies, Alice B Gottlieb
BACKGROUND: Patients with psoriasis are at increased risk of liver function abnormalities. OBJECTIVE: Explore rates of hepatic treatment-emergent adverse events (TEAEs) and changes in liver parameters in bimekizumab-treated patients with psoriasis. METHODS: Data are reported from five phase 3/3b trials over 2 years. Hepatic TEAEs, laboratory elevations in alanine aminotransferase (ALT) or aspartate aminotransferase (AST), and changes in clinical markers of liver fibrosis (Fibrosis-4 [FIB-4] Index and AST to Platelet Ratio Index [APRI]) are reported...
April 6, 2024: Journal of the American Academy of Dermatology
https://read.qxmd.com/read/38586860/a-retrospective-observational-study-of-patterns-of-biologic-drug-change-in-inflammatory-bowel-disease
#38
JOURNAL ARTICLE
Mahmoud Mosli
INTRODUCTION: Multiple therapies are currently available for inflammatory bowel disease (IBD); it is therefore crucial to understand patterns of drug change. This study aimed to examine the patterns of biological drug change and identify predictors of change in patients with IBD. METHODS: We performed a retrospective study of patients diagnosed with IBD who were initiated on treatment with biologics between June 2017 and October 2022. The study's primary objective was to describe biologic drug change patterns...
2024: Inflammatory Intestinal Diseases
https://read.qxmd.com/read/38586820/cronkhite-canada-syndrome-a-rare-cause-of-gastrointestinal-polyposis-with-response-to-emerging-therapy
#39
Kevork Khadarian, Rish Pai, Niloy Jewel Samadder
A 70-year-old man presented to the clinic with a 6-month history of dysgeusia, followed by chronic, non-bloody diarrhea and 45 lb unintentional weight loss. Esophagogastroduodenoscopy discovered confluent nodularity in the gastric antrum and examined duodenum, but a normal esophagus. Colonoscopy uncovered patches of polypoid nodular mucosa throughout the entire colon. Biopsies of the nodular mucosa were consistent with hamartomatous polyps while biopsies of the intervening, normal-appearing mucosa demonstrated edema with crypt architectural distortion...
April 2024: ACG Case Reports Journal
https://read.qxmd.com/read/38586767/very-early-onset-of-fistulizing-inflammatory-bowel-disease-with-ripk1-mutation-a-case-report
#40
Rola K Bsharat, Mahmoud E AbuBshara, Islam H Karajeh, Amal F Bast, Taima M Aljabari, Osama Q Qumsieh, Haytham M Abumohsen
Infantile inflammatory bowel disease (IBD) is a very rare subgroup of IBD that develops in children younger than two years with genetic susceptibility, especially in those with monogenic defects. This type, when compared with IBD in older children, is more resistant to conventional medical treatment and presents with more complications that require more surgical interventions. Our patient is a male with first-degree consanguineous parents. He was 16 months old when he presented with multiple perianal fistulas, fissures, abscesses, diarrhea, fever, and failure to thrive...
March 2024: Curēus
keyword
keyword
1884
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.